JPRN-jRCT2032220377
进行中（未招募）
未知
roLift System post-marketing surveillance
Kadono Yoshihiko0 个研究点目标入组 200 人2022年10月14日
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Benign prostatic hyperplasia with lower urinary tract symptoms (LUTS)
- 发起方
- Kadono Yoshihiko
- 入组人数
- 200
- 状态
- 进行中（未招募）
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients diagnosed with benign prostatic hyperplasia and with lower urinary tract symptoms (LUTS) who used this product according to IFU. Regardless of whether it is lateral or median lobe.
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
招募中
4 期
A post marketing study to evaluate safety and effectiveness of Remogliflozin and Remogliflozin-Metformin Combination in treatment of Diabetes patientsHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2019/11/022062Glenmark Pharmaceuticals Ltd
招募中
不适用
Rezum System Post Market surveillancePatients with bothersome urinary symptoms associated with BPH.JPRN-UMIN000048675Boston Scientific Japan K.K.100
已完成
4 期
A post-marketing study of the marketed product Maxtra® P syrup for the evaluation of safety and effects in children having common cold.Health Condition 1: J00- Acute nasopharyngitis [common cold]CTRI/2021/02/031189Zuventus Healthcare Limited200
已完成
4 期
A post-marketing study of the marketed product Maxtra® P Tablets for the evaluation of safety and effects in children having common cold.CTRI/2021/02/031390Zuventus Healthcare Limited200
进行中（未招募）
4 期
To collect safety data in patients with Wet-AMD after giving aflibercept injection in affected eye.CTRI/2017/12/010876Bayer Pharmaceutical Pvt Ltd